Dupilumab in COPD: A Pooled Analysis of Emergency Department Visits, Hospital Admissions, and Systemic Corticosteroid Use
- Journal
- American Journal of Respiratory and Critical Care Medicine (Q1)
- Published
- 18 May 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Surya P Bhatt, Fernando J Martinez, Imran Satia, Antonio Anzueto, Jean Bourbeau, Alberto Papi, et al.
- PMID
- 42153327
- DOI
- 10.1093/ajrccm/aamag227
Why clinicians should know about it
- Picked for Emergency Medicine (top studies of the week, 22 November 2026): Dupilumab reduces ED visits/hospitalisations in COPD
Abstract
RATIONALE: In chronic obstructive pulmonary disease, exacerbations drive morbidity, healthcare resource utilization, and mortality. Hospitalization and emergency department visits reflect acute clinical instability. Systemic corticosteroids are usually prescribed for exacerbations, but cumulative exposure is a concern. OBJECTIVES: To evaluate the effect of dupilumab on emergency department visits/hospital admissions and systemic corticosteroid use in patients experiencing exacerbations. METHODS: BOREAS and NOTUS, two phase 3, randomized, double-blind, placebo-controlled trials, enrolled patients (40-85 years) with chronic obstructive pulmonary disease, moderate-to-severe airflow limitation, and type 2 inflammation (screening blood eosinophil count ≥ 300 cells/µL). Patients received dupilumab 300 mg (N = 938) or placebo (N = 936) for 52 weeks. Systemic corticosteroid use and annualized rate and time to first emergency department visit/hospital admission were assessed. MEASUREMENTS AND MAIN RESULTS: Dupilumab versus placebo reduced emergency department visits/hospital admissions of any duration by 38% (relative risk: 0.62 [95% confidence interval: 0.43-0.90]; P = .0121), delayed time to first event, and reduced risk of a first event by 45% (hazard ratio: 0.55 [95% confidence interval: 0.38-0.78]; P = .0010). Compared with placebo, systemic corticosteroid use was reduced in patients treated with dupilumab who experienced severe exacerbations by 42% (relative risk: 0.58 [95% confidence interval: 0.38-0.89]; P = .0126) and moderate exacerbations by 28% (relative risk: 0.72 [95% confidence interval: 0.60-0.87]; P = .0005). CONCLUSIONS: Dupilumab reduced emergency department visits/hospital admissions of any duration. Patients who experienced moderate and/or severe exacerbations required fewer systemic corticosteroids with dupilumab compared with placebo.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.